Skip to main
PSNL

Personalis Inc (PSNL) Stock Forecast & Price Target

Personalis Inc (PSNL) Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 83%
Buy 0%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

Personalis Inc. reported a significant 41% quarter-over-quarter increase in NeXT Personal Dx volumes in Q4'25, surpassing prior expectations and indicating robust demand for its genomic sequencing and analytics solutions. The recent announcement of Medicare coverage and pricing for the NeXT Personal MRD test, particularly for breast cancer, has further bolstered investor confidence, contributing to a 28% increase in share value. Additionally, the anticipated acceleration of marketing efforts by commercial partner Tempus is expected to drive even higher volumes and revenue growth moving forward.

Bears say

Personalis Inc's outlook is negatively impacted by a lower revenue guidance for Q4 2025, attributed to a general slowdown in the biopharma sector and logistical challenges with global sample handling. Additionally, the company has faced a year-over-year decline in revenue from its pharmaceutical services, significantly influenced by the conclusion of enrollment in Moderna's Phase III melanoma trial. Despite raising $109 million from an ATM facility, concerns regarding ongoing losses, debt on the balance sheet, and the risk of being unable to achieve long-term profitability further contribute to the unfavorable sentiment surrounding Personalis's financial health.

Personalis Inc (PSNL) has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 83% of analysts recommend a Strong Buy, 0% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Personalis Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Personalis Inc (PSNL) Forecast

Analysts have given Personalis Inc (PSNL) a Strong Buy based on their latest research and market trends.

According to 6 analysts, Personalis Inc (PSNL) has a Strong Buy consensus rating as of Mar 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Personalis Inc (PSNL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.